Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...
Amgen: Xaluritamig is a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager that our partner Amgen is advancing for the treatment of patients with prostate cancer. In the fourth quarter of 2024 ...
In collaboration, Amgen (NASDAQ:AMGN) is initiating a Phase III mCRPC study of xaluritamig (STEAP1xCD3), and Johnson & Johnson is conducting Phase I studies of two CD28 bispecific antibodies.
In collaboration, Amgen (NASDAQ:AMGN) is initiating a Phase III mCRPC study of xaluritamig (STEAP1xCD3), and Johnson & Johnson is conducting Phase I studies of two CD28 bispecific antibodies. Xencor's ...
Recent Partnership Developments Amgen: Xaluritamig is a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager that our partner Amgen is advancing for the treatment of patients with prostate cancer. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback